Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

Now Viewing

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights^® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

This segment discusses how concerns about immune resistance affect optimal timing of immune checkpoint inhibitor therapy for melanoma. Khushalani explains that with adjuvant treatment for resected disease, the goal is preventing metastases from micrometastatic disease. Despite therapy, some patients still experience relapse while on adjuvant therapy.It is unclear whether relapse during adjuvant therapy represents primary resistance or what the significance is of the time interval between completing adjuvant treatment and relapse.

Currently, the field arbitrarily uses a 6-month interval after finishing adjuvant anti–PD-1 therapy to distinguish patients more likely to benefit from repeat immune checkpoint blockade (relapse > 6 months later) vs those who may have primary refractory disease (relapse within 6 months). Further research is needed to better define these patient cohorts and resistance patterns.

Video synopsis is AI generated and reviewed by OncLive^® editorial staff.